ThermoGenesis Holdings, Inc.

OTCPK:THMO Stock Report

Market Cap: US$9.5k

ThermoGenesis Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Chris Xu

Chief executive officer

US$520.0k

Total compensation

CEO salary percentage100.0%
CEO tenure8.1yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure8.8yrs

Recent management updates

Recent updates

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Apr 17
It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

ThermoGenesis reports Q2 results

Aug 11

Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?

Oct 20
Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?

Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?

May 31
Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?

When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?

Apr 06
When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?

Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt

Feb 10
Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Dec 15
Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

ThermoGenesis EPS misses by $0.27, misses on revenue

Nov 12

CEO Compensation Analysis

How has Chris Xu's remuneration changed compared to ThermoGenesis Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$15m

Dec 31 2023US$520kUS$520k

-US$18m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$699kUS$519k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$9m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$748kUS$500k

-US$11m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$2mUS$505k

-US$16m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$12m

Dec 31 2019US$472kUS$472k

-US$9m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$13m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$653kUS$460k

-US$40m

Sep 30 2018n/an/a

-US$32m

Jun 30 2018n/an/a

-US$32m

Mar 31 2018n/an/a

-US$6m

Dec 31 2017US$1mUS$216k

-US$6m

Compensation vs Market: Chris's total compensation ($USD520.00K) is about average for companies of similar size in the US market ($USD654.40K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Xu (53 yo)

8.1yrs

Tenure

US$520,000

Compensation

Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph D., serves as Chief Executive Officer and Chairman at ImmuneCyte Life Sciences, Inc. Dr. Xu is the Founder, Chairman and Chief Executive Officer of Boyalife...

Board Members

NamePositionTenureCompensationOwnership
Xiaochun Xu
Chairman of the Board & CEO8.8yrsUS$520.00kno data
Solomon Hamburg
Member of Clinical & Scientific Advisory Board10.6yrsno datano data
Lars Norgren
Member of Clinical Advisory Board8.8yrsno datano data
Biao Xi
Independent Director1.4yrsUS$10.00kno data

8.8yrs

Average Tenure

Experienced Board: THMO's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:13
End of Day Share Price 2024/12/20 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ThermoGenesis Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Jon HickmanMDB Capital Group LLC